These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24766516)

  • 21. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.
    Liberatore GT; Samson A; Bladin C; Schleuning WD; Medcalf RL
    Stroke; 2003 Feb; 34(2):537-43. PubMed ID: 12574572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.
    Reddrop C; Moldrich RX; Beart PM; Farso M; Liberatore GT; Howells DW; Petersen KU; Schleuning WD; Medcalf RL
    Stroke; 2005 Jun; 36(6):1241-6. PubMed ID: 15879331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What's new in stroke prevention and treatment.
    Weimar C; Diener HC
    Expert Rev Neurother; 2006 Feb; 6(2):185-93. PubMed ID: 16466298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desmoteplase After Ischemic Stroke in Patients With Occlusion or High-Grade Stenosis in Major Cerebral Arteries.
    Lindsberg PJ; Caso V
    Stroke; 2016 Mar; 47(3):901-3. PubMed ID: 26846865
    [No Abstract]   [Full Text] [Related]  

  • 25. Desmoteplase: discovery, insights and opportunities for ischaemic stroke.
    Medcalf RL
    Br J Pharmacol; 2012 Jan; 165(1):75-89. PubMed ID: 21627637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desmoteplase for late treatment of stroke: still in the dark.
    Hill MD; Menon BK
    Lancet Neurol; 2015 Jun; 14(6):560-1. PubMed ID: 25937441
    [No Abstract]   [Full Text] [Related]  

  • 27. Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2).
    Liebeskind DS
    Stroke; 2009 Sep; 40(9):3156-8. PubMed ID: 19608990
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
    Li X; Ling L; Li C; Ma Q
    Medicine (Baltimore); 2017 May; 96(18):e6667. PubMed ID: 28471961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute stroke management in the elderly.
    Zeevi N; Chhabra J; Silverman IE; Lee NS; McCullough LD
    Cerebrovasc Dis; 2007; 23(4):304-8. PubMed ID: 17199089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of alteplase in the treatment of ischaemic stroke.
    Acheampong P; Ford GA
    Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):271-81. PubMed ID: 22248305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of desmoteplase-induced fibrinolytic activity in vitro.
    Hoffmann JJ; Kops O
    J Thromb Thrombolysis; 2005 Aug; 20(1):23-6. PubMed ID: 16133891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific therapies for ischaemic stroke: rTPA and others.
    Toni D; Lorenzano S; Sacchetti ML; Fiorelli M; De Michele M; Principe M
    Neurol Sci; 2005 May; 26 Suppl 1():S26-8. PubMed ID: 15883686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombolysis in acute stroke.
    del Zoppo GJ
    Neurologia; 1995 Dec; 10 Suppl 2():37-47. PubMed ID: 8714449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms.
    Amaro S; Cánovas D; Castellanos M; Gállego J; Martí-Fèbregas J; Segura T; Chamorro A
    Int J Stroke; 2010 Aug; 5(4):325-8. PubMed ID: 20636718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.
    Kadir RRA; Bayraktutan U
    Cell Mol Neurobiol; 2020 Apr; 40(3):347-355. PubMed ID: 31552559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological therapy of acute ischaemic stroke: Achievements and problems.
    Moretti A; Ferrari F; Villa RF
    Pharmacol Ther; 2015 Sep; 153():79-89. PubMed ID: 26079382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment.
    Diener HC; Foerch C; Riess H; Röther J; Schroth G; Weber R
    Lancet Neurol; 2013 Jul; 12(7):677-88. PubMed ID: 23726849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.
    Logallo N; Kvistad CE; Nacu A; Thomassen L
    CNS Drugs; 2016 Feb; 30(2):101-8. PubMed ID: 26798040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous thrombolysis for ischemic stroke in recurrent oligodendroglioma: a case report.
    Dafer RM; Paleologos N; Lynch D
    J Stroke Cerebrovasc Dis; 2014; 23(5):1235-8. PubMed ID: 24103669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.